• Its new drug, an inhibitor of the enzyme cathepsin K, showed promising results in a mid-stage trial earlier this year.

    FORBES: Magazine Article

  • To be specific, Merck (MRK) will test a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, which the drugmaker notes is the first drug with this type of mechanism to advance to this stage of clinical research.

    FORBES: Merck Makes A 'Speculative' Step Into Alzheimer's

  • Recent examples: molecules to target drug-resistant bacteria and a kinase inhibitor to zap the enzyme responsible for tumor growth.

    FORBES: Careers

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定